We’re on a mission to develop novel therapies for SCN2A—join us
Receive updates about the latest research and ways to get involved
Sign Up
Praxis Precision Medicines is a biotechnology company developing experimental new medicine for patients and families impacted by mutations in the SCN2A gene. We are using an antisense oligonucleotide (ASO) to specifically target the SCN2A gene. In a second program, we are using a persistent sodium current blocker. We invite you to join us as we progress these exciting new potential treatments through clinical development.
SCN2A Parent Survey
We want to learn from parents of children with mutations in the SCN2A gene. By taking our 15-minute anonymous survey, you will help inform our research efforts to develop new medicines for SCN2A. The results will be shared with the SCN2A community.
Take the Survey
SCN2A Parent Survey
We want to learn from parents of children with mutations in the SCN2A gene. By taking our 15-minute anonymous survey, you will help inform our research efforts to develop new medicines for SCN2A. The results will be shared with the SCN2A community.
Take the Survey
Meet Praxis
Praxis is passionate about developing potential new medicines for patients with SCN2A disorders.
Learn More
SCN2A Overview
Learn about the SCN2A gene, and signs and symptoms of SCN2A disorders. Plus, find support and other resources.
Learn More
For Physicians
Find out how to order no-cost genetic epilepsy testing panels and explore current clinical trial opportunities to share with families caring for children with SCN2A disorders.
Learn More
Community News
Get the latest SCN2A community updates and find out how you can impact future SCN2A research.
